Network pharmacology: the next paradigm in  drug discovery.
The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets. However, many effective drugs act via modulation of multiple proteins rather than single targets. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This new appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development--efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets. However, the rational design of polypharmacology faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties. Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacology.
Hopkins
Andrew L
AL
Division of Biological Chemistry and Drug Discovery, College of Life Science, University of Dundee, Dundee, UK. a.hopkins@dundee.ac.uk
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use* / Q000633:toxicity; D016503:Drug Delivery Systems; D015195:Drug Design; D023281:Genomics; D006801:Humans; D010600:Pharmacology / Q000379:methods / Q000639:trends*; D013329:Structure-Activity Relationship; D049490:Systems Biology
D000970:Antineoplastic Agents